Recursion Pharmaceuticals Inc (RXRX)
8.84
+0.05
(+0.57%)
USD |
NASDAQ |
May 03, 16:00
8.86
+0.02
(+0.23%)
After-Hours: 20:00
Recursion Pharmaceuticals Enterprise Value: 1.684B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.684B |
| May 02, 2024 | 1.672B |
| May 01, 2024 | 1.567B |
| April 30, 2024 | 1.445B |
| April 29, 2024 | 1.534B |
| April 26, 2024 | 1.515B |
| April 25, 2024 | 1.449B |
| April 24, 2024 | 1.473B |
| April 23, 2024 | 1.416B |
| April 22, 2024 | 1.393B |
| April 19, 2024 | 1.334B |
| April 18, 2024 | 1.346B |
| April 17, 2024 | 1.362B |
| April 16, 2024 | 1.386B |
| April 15, 2024 | 1.438B |
| April 12, 2024 | 1.583B |
| April 11, 2024 | 1.703B |
| April 10, 2024 | 1.623B |
| April 09, 2024 | 1.743B |
| April 08, 2024 | 1.721B |
| April 05, 2024 | 1.691B |
| April 04, 2024 | 1.658B |
| April 03, 2024 | 1.705B |
| April 02, 2024 | 1.667B |
| April 01, 2024 | 1.808B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.949B |
| March 27, 2024 | 1.996B |
| March 26, 2024 | 2.031B |
| March 25, 2024 | 2.080B |
| March 22, 2024 | 2.071B |
| March 21, 2024 | 2.109B |
| March 20, 2024 | 2.207B |
| March 19, 2024 | 2.132B |
| March 18, 2024 | 2.289B |
| March 15, 2024 | 2.242B |
| March 14, 2024 | 2.139B |
| March 13, 2024 | 2.186B |
| March 12, 2024 | 2.083B |
| March 11, 2024 | 2.043B |
| March 08, 2024 | 2.235B |
| March 07, 2024 | 2.226B |
| March 06, 2024 | 2.266B |
| March 05, 2024 | 2.404B |
| March 04, 2024 | 2.496B |
| March 01, 2024 | 2.615B |
| February 29, 2024 | 2.768B |
| February 28, 2024 | 2.646B |
| February 27, 2024 | 3.251B |
| February 26, 2024 | 3.073B |
| February 23, 2024 | 2.747B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
276.51M
Minimum
May 11 2022
6.341B
Maximum
Jul 13 2021
1.861B
Average
1.412B
Median
Feb 14 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 722.23B |
| Palatin Technologies Inc | 24.56M |
| Oragenics Inc | 3.216M |
| Actinium Pharmaceuticals Inc | 182.80M |
| Marinus Pharmaceuticals Inc | 5.632M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -93.00M |
| Revenue (Quarterly) | 10.62M |
| Total Expenses (Quarterly) | 109.55M |
| EPS Diluted (Quarterly) | -0.42 |
| Gross Profit Margin (Quarterly) | 6.99% |
| Profit Margin (Quarterly) | -875.3% |
| Earnings Yield | -17.76% |
| Normalized Earnings Yield | -17.76 |